Experimental combo therapy targets multiple cancers in new trial

NCT ID NCT06814496

Recruiting now Disease control Sponsor: University of Arizona Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusions along with radiation, either at the same time or one after the other. The main goal is to check for serious side effects, and a smaller part of the study will look at whether the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tarlatamab (a drug that helps immune cells attack cancer) and radiation therapy
What this could lead to: If successful, this could point toward a new treatment option for several hard-to-treat cancers that have a specific protein (DLL3) on their surface.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. Combining tarlatamab with radiation could cause serious side effects like inflammation or nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary cervical cancer cutaneous neuroendocrine carcinoma esthesioneuroblastoma Esthesioneuroblastoma, Olfactory glioblastoma glioma susceptibility 1 medullary thyroid gland carcinoma melanoma non-small cell lung carcinoma pulmonary large cell neuroendocrine carcinoma sinonasal undifferentiated carcinoma testicular cancer urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER CERVICAL CANCER ESTHESIONEUROBLASTOMA GLIOBLASTOMA MULTIFORME LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG MEDULLARY THYROID CANCER MELANOMA MERKEL CELL CARCINOMA NON-SMALL CELL LUNG CANCER SINONASAL UNDIFFERENTIATED CARCINOMA TESTICULAR CANCER

Contacts and locations

Locations

Arizona Cancer Center at UMC North/University Medical Center
RECRUITING

Tucson, Arizona, 85719, United States
University of Washington Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.